These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 28922157)

  • 1. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study.
    Inui Y; Ito K; Kato T;
    J Alzheimers Dis; 2017; 60(3):877-887. PubMed ID: 28922157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Outcomes in Mild Cognitive Impairment by Using 18F-FDG-PET: A Multicenter Study.
    Ito K; Fukuyama H; Senda M; Ishii K; Maeda K; Yamamoto Y; Ouchi Y; Ishii K; Okumura A; Fujiwara K; Kato T; Arahata Y; Washimi Y; Mitsuyama Y; Meguro K; Ikeda M;
    J Alzheimers Dis; 2015; 45(2):543-52. PubMed ID: 25589723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI.
    Tripathi M; Tripathi M; Parida GK; Kumar R; Dwivedi S; Nehra A; Bal C
    Neurol India; 2019; 67(5):1310-1317. PubMed ID: 31744965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET for Prediction of Conversion to Alzheimer's Disease Dementia in People with Mild Cognitive Impairment: An Updated Systematic Review of Test Accuracy.
    Smailagic N; Lafortune L; Kelly S; Hyde C; Brayne C
    J Alzheimers Dis; 2018; 64(4):1175-1194. PubMed ID: 30010119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of individual-based FDG-PET volume of interest in predicting conversion from mild cognitive impairment to dementia.
    Huang SH; Hsiao WC; Chang HI; Ma MC; Hsu SW; Lee CC; Chen HJ; Lin CH; Huang CW; Chang CC
    BMC Med Imaging; 2024 Mar; 24(1):75. PubMed ID: 38549082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subtypes: Stratification Based on Imaging Biomarkers.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Alzheimers Dis; 2016 Apr; 52(4):1385-401. PubMed ID: 27079727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET.
    Stonnington CM; Chen Y; Savage CR; Lee W; Bauer RJ; Sharieff S; Thiyyagura P; Alexander GE; Caselli RJ; Locke DEC; Reiman EM; Chen K
    J Alzheimers Dis; 2018; 63(2):603-615. PubMed ID: 29630550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting MCI progression with FDG-PET and cognitive scores: a longitudinal study.
    Teng L; Li Y; Zhao Y; Hu T; Zhang Z; Yao Z; Hu B;
    BMC Neurol; 2020 Apr; 20(1):148. PubMed ID: 32316912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.
    Kawachi T; Ishii K; Sakamoto S; Sasaki M; Mori T; Yamashita F; Matsuda H; Mori E
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):801-9. PubMed ID: 16550383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.